drugset / Trial / NCT03714828
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is single arm Phase 2, single center study of talimogene laherparepvec (TVEC) to treat low risk cutaneous squamous cell carcinomas (cSCC).
Timeline
- Start
- 2018-12-20
- Primary completion
- 2023-07-19
- Completion
- 2023-07-19
Outcome
Met primary endpoint
registry p = 0.0005; Overall Response Rate 100; One-sample binomial test NCT03714828 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talimogene Laherparepvec | Other / unclassified | 0.5 ml | Other |
| Subject | Talimogene Laherparepvec | Other / unclassified | 4 ml | Other |